There is increasing interest in gluten-degrading enzymes for use during food and drink processing. The industrially available enzymes usually work best at low to ambient temperatures. However, food manufacturing is often conducted at higher temperatures. Therefore, thermostable gluten-degrading enzymes are of great interest. We have identified a new thermostable gluten-degrading proline-specific prolyl endoprotease from the archaea Thermococcus kodakarensis. We then cloned and expressed it in Escherichia coli. The prolyl endoprotease was found to have a size of 70.1 kDa. The synthetic dipeptide Z-Gly-Pro-p-nitroanilide was used to characterize the prolyl endoprotease and it had maximum activity at pH 7 and 77°C. The Vmax, Km and kcat values of the purified prolyl endoprotease were calculated to be 3.14 mM/s, 1.10 mM and 54 s-1, respectively. When the immunogenic gluten peptides PQPQLPYPQPQLPY (α-gliadin) and SQQQFPQPQQPFPQQP (γ-hordein) were used as substrates, the prolyl endoprotease was able to degrade these. Furthermore, gluten in wort was reduced when the prolyl endoprotease was used during mashing of barley malt. The discoveries open up new food processing possibilities and further the understanding of proline-specific protease diversity.

Download full-text PDF

Source
http://dx.doi.org/10.1093/femsle/fnac006DOI Listing

Publication Analysis

Top Keywords

prolyl endoprotease
28
thermococcus kodakarensis
8
gluten-degrading enzymes
8
thermostable gluten-degrading
8
prolyl
7
endoprotease
7
characterization gluten-degrading
4
gluten-degrading prolyl
4
endoprotease thermococcus
4
kodakarensis increasing
4

Similar Publications

Article Synopsis
  • The editorial discusses celiac disease (CeD), an autoimmune condition primarily affecting individuals with a genetic predisposition, characterized by gluten intolerance and symptoms like abdominal pain and diarrhea.* -
  • Patients with CeD must adhere to a lifelong gluten-free diet, which can significantly impact their quality of life and financial well-being.* -
  • The piece highlights the challenges in finding effective treatments due to the complex nature of CeD's pathogenesis and reviews both the disease's mechanisms and the current state of experimental and improved drug options.*
View Article and Find Full Text PDF

prolyl endopeptidase in celiac disease.

World J Gastroenterol

June 2024

Interdisciplinary Department of Medicine, Section of Microbiology and Virology, University of Bari "Aldo Moro", Bari 70124, Italy.

We comment here on the article by Stefanolo entitled "Effect of prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet", published in the . Celiac disease is a well-recognized systemic autoimmune disorder. In genetically susceptible people, the most evident damage is located in the small intestine, and is caused and worsened by the ingestion of gluten.

View Article and Find Full Text PDF

Background: The gluten-free diet (GFD) has limitations, and there is intense research in the development of adjuvant therapies.

Aim: To examine the effects of orally administered prolyl endopeptidase protease (AN-PEP) on inadvertent gluten exposure and symptom prevention in adult celiac disease (CeD) patients following their usual GFD.

Methods: This was an exploratory, double-blind, randomized, placebo-controlled trial that enrolled CeD patients on a long-term GFD.

View Article and Find Full Text PDF

Background: Celiac disease (CD) is a gluten-sensitive chronic autoimmune enteropathy. A strict life-long gluten-free diet is the only efficient and accepted treatment until now. However, maintaining a truly gluten-free status is both difficult and costly, often resulting in a social burden for the person.

View Article and Find Full Text PDF

Beer is a beverage that contains gluten and cannot be consumed by people with celiac disease. In this context, the enzyme prolyl endoprotease (PEP) can be used to reduce the gluten content in beer. The present study aimed to produce the PEP from Aspergillus sp.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!